Triptorelin market value is predicted to reach USD 1.49 billion by 2032, according to a new research report by Global Market Insights Inc. Rising awareness about precocious puberty is a key driver ...

Discover comprehensive details about Triptorelin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Review the side-effects of Triptorelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

(HealthDay News) — For female patients with childhood-onset systemic lupus erythematosus (SLE) who require treatment with cyclophosphamide, sustained complete ovarian suppression is achieved in 90% of ...

Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...

Women with polycystic ovary syndrome have less increase in follicle-stimulating hormone after triptorelin administration during in vitro fertilization than women without PCOS, according to data from ...

Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with ...

March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...

The global triptorelin market is set for substantial growth, according to the latest market analysis report. Forecasts indicate that the market, valued at approximately USD 955.50 million in 2023, is ...

Chemotherapy for breast cancer in premenopausal women causes menopause (premature ovarian failure) in a variable proportion of patients, ranging from 0% to 90% depending on the treatment received and ...

Gonadotropin-releasing hormone (GnRH) agonists are more effective and safe compared to estrogens and anti-androgens used to attain medical castration. GnRH agonists offer slow-release formulations ...